CITI/CALL/ELI LILLY & CO/560/0.1/16.01.25 | Delayed Deutsche Boerse AG 18:41:29 11/07/2024 BST | ||
| 35.5 EUR | -3.35% |
|
| Current month | +2.39% | ||
| 1 month | +18.33% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 11/07/24 | 35.5 | -3.35% |
| 10/07/24 | 36.73 | +3.03% |
| 09/07/24 | 35.65 | +2.68% |
| 08/07/24 | 34.72 | +0.84% |
| 05/07/24 | 34.43 | +4.40% |
Delayed Quote Deutsche Boerse AG
Last update July 11, 2024 at 06:41 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Citi
|
| WKN | KH76Y6 |
| ISIN | DE000KH76Y67 |
| Date issued | 19/07/2023 |
| Strike | 560 $ |
| Maturity | 16/01/2025 (189 Days) |
| Parity | 10 : 1 |
| Emission price | 2.61 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 37.14 € |
|---|---|
| Lowest since issue | 2.78 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
934.1
USD
Average target price
887.2
USD
Spread / Average Target
-5.03%
- Stock Market
- Warrants
- Warrant
